Dr. John Streiff is chief chemistry officer of DiscoveryBioMed, Inc. (DBM), a biotechnology company in Birmingham, Alabama that is focused on leveraging diseased and healthy human cells as platform technologies for ‘humanized’ drug discovery. Dr. Streiff leads DBM’s cell-based drug discovery projects by deploying its compound library of 75,000 compounds accumulated from seven different commercial vendors that maximizes chemical diversity of small molecules. Dr. Streiff leads the high-throughput screening and validation assays together with the DBM biology team, and he performs bioinformatics for ‘hit picking’ as well as cheminformatics to identify and deepen hit-to-lead chemical classes and select ‘best in class’ target-binding scaffolds to virtually screen larger chemical libraries. He also calculates the key chemical metrics that predict human blood-brain barrier (BBB) permeation critical to the development of inhibitors development for Parkinson’s disease. Dr. Streiff has been in this role at DBM for 12 years.